Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: a Southwest Oncology Group Pilot Study.
We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance. We conclude that this combination chemotherapy regimen is not a valuable salvage treatment for patients with non-Hodgkin's lymphoma.
D000328:Adult; D000368:Aged; D000609:Aminoacridines / Q000008:administration & dosage; D000677:Amsacrine; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004064:Digestive System / Q000187:drug effects; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008935:Mitoguazone / Q000008:administration & dosage
D000609:Aminoacridines; D000677:Amsacrine; D008935:Mitoguazone; D002945:Cisplatin